Get the Stockscreener App
60.35
2.65%
1.56
After Hours:
60.34
-0.010
-0.02%
Biomarin Pharmaceutical Inc stock is traded at $60.35, with a volume of 1.28M.
It is up +2.65% in the last 24 hours and up +6.31% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$58.79
Open:
$59.64
24h Volume:
1.28M
Relative Volume:
0.63
Market Cap:
$11.66B
Revenue:
$3.29B
Net Income/Loss:
$268.74M
P/E Ratio:
44.04
EPS:
1.3704
Net Cash Flow:
$759.12M
1W Performance:
+5.47%
1M Performance:
+6.31%
6M Performance:
-1.57%
1Y Performance:
+5.12%
1-Day Range:
$58.63
$60.54
1-Week Range:
$57.25
$60.54
52-Week Range:
$49.26
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.35 | 11.36B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Resumed | Morgan Stanley | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BMRN Maintained by RBC Capital -- Price Target Lowered to $62 - GuruFocus
BioMarin Pharmaceutical updates its rare disease pipeline. Focus on long-term growth and innovation - AD HOC NEWS
RBC Capital Lowers BioMarin Pharmaceutical Price Target to $62 From $66, Maintains Sector Perform Rating - marketscreener.com
Trading Systems Reacting to (BMRN) Volatility - Stock Traders Daily
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating - ChartMill
BMRNBiomarin Pharmaceutical Inc Options - Finviz
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
The top 12 companies hiring in biopharma now - BioSpace
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Value-Defensive Index - marketscreener.com
BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued? - Sahm
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout | AI
BioMarin Pharmaceutical, Friday analyst angle, shares in focus - Ad-hoc-news.de
BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN
BMRN Stock Price, Quote & Chart - ChartMill
Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh - TradingView
BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN) - TradingView
Price to sales forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
BMRN Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
Price to book forward of BioMarin Pharmaceutical Inc. – GETTEX:BM8 - TradingView
Price to book forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
Price to earnings forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN - TradingView
How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing - Stock Traders Daily
BioMarin Pharmaceutical Inc (BMRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment - Insider Monkey
10 Most Promising Stocks with Highest Upside Potential - Insider Monkey
BioMarin stock maintained at Neutral by H.C. Wainwright on trial data - Investing.com UK
Stifel reiterates Hold on BioMarin stock, keeps $68 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Hold on BioMarin stock, keeps $68 price target - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unpacking A 60% Upside Potential - DirectorsTalk Interviews
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Chart - ChartMill
BioMarin Pharmaceutical Inc (BMRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Institutional Confidence - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioMarin Pharmaceutical Inc - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioMarin presents three-year VOXZOGO data for hypochondroplasia By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. Presents New Three-Year VOXZOGO Data in Hypochondroplasia and BMN 333 Early Results At ENDO 2026 - marketscreener.com
BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments - marketscreener.com
BioMarin presents three-year VOXZOGO data for hypochondroplasia - Investing.com
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - PR Newswire
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring a Potential 57% Upside Opportunity - DirectorsTalk Interviews
(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):